Aelix Therapeutics SL, of Barcelona, Spain, signed a clinical research collaboration with Gilead Sciences Inc., of Foster City, Calif., to jointly evaluate investigational products in a clinical study aimed at achieving a functional cure of HIV infection. The collaboration will enable the conduct of an experiment to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing Aelix's HTI T-cell vaccine and Gilead´s Toll-like receptor 7 agonist, vesatolimod, in HIV-infected individuals on antiretroviral therapy.